Quarterly report · Q1

Period2023-04-01 → 2023-06-30
Filed2023-08-10
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥57.4bn2023-04-01 → 2023-06-30Cons.Revenue IFRS
Revenue¥230.8bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥57.0bn2022-04-01 → 2022-06-30Cons.Revenue IFRS
Operating income¥18.0bn2023-04-01 → 2023-06-30Cons.Operating profit loss IFRS
Operating income¥18.7bn2022-04-01 → 2022-06-30Cons.Operating profit loss IFRS
Profit before tax¥19.8bn2023-04-01 → 2023-06-30Cons.Profit loss before tax IFRS
Profit before tax¥74.3bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥19.7bn2022-04-01 → 2022-06-30Cons.Profit loss before tax IFRS
Net income (owners)¥12.4bn2023-04-01 → 2023-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥49.0bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥12.1bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income¥13.6bn2023-04-01 → 2023-06-30Cons.Profit loss IFRS
Net income¥13.5bn2022-04-01 → 2022-06-30Cons.Profit loss IFRS
Total assets¥439.6bnat 2023-06-30Cons.Assets IFRS
Total assets¥400.6bnat 2023-03-31Cons.Assets IFRS
Total assets¥357.5bnat 2022-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥110.9bnat 2023-06-30Cons.Liabilities IFRS
Total liabilities¥91.1bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥328.8bnat 2023-06-30Cons.Equity IFRS
Net assets / equity¥309.5bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥275.1bnat 2022-06-30Cons.Equity IFRS
Net assets / equity¥264.0bnat 2022-03-31dCons.Equity IFRS
Equity (owners)¥316.8bnat 2023-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥302.6bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥268.8bnat 2022-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥130.7bnat 2023-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥118.3bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥88.8bnat 2022-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥104.3bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥12.0bn2023-04-01 → 2023-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥57.1bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥9.4bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥18.2bn2023-04-01 → 2023-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥21.9bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥14.7bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥16.4bn2023-04-01 → 2023-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥22.8bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥12.5bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥18.292023-04-01 → 2023-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥72.222022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥17.862022-04-01 → 2022-06-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥18.272023-04-01 → 2023-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥72.172022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥17.852022-04-01 → 2022-06-30Cons.Diluted earnings loss per share IFRS
Equity ratio72.1%at 2023-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio75.5%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio75.2%at 2022-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-06-30−¥1.0bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-06-30−¥1.0bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-06-30¥167m
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue2023-04-01 → 2023-06-30¥5.6bn
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue external2023-04-01 → 2023-06-30¥5.6bn
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥16m
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentsegment profit2023-04-01 → 2023-06-30¥2.7bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue2023-04-01 → 2023-06-30¥7.0bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue external2023-04-01 → 2023-06-30¥6.8bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥114m
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentsegment profit2023-04-01 → 2023-06-30¥1.9bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue2023-04-01 → 2023-06-30¥21.9bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue external2023-04-01 → 2023-06-30¥21.1bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥868m
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentsegment profit2023-04-01 → 2023-06-30¥8.9bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue2023-04-01 → 2023-06-30¥15.7bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue external2023-04-01 → 2023-06-30¥15.7bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥11m
jpcrp040300-q1r_E05425-000Overseasreportable segmentsegment profit2023-04-01 → 2023-06-30¥3.7bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue2023-04-01 → 2023-06-30¥7.7bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue external2023-04-01 → 2023-06-30¥7.7bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥3m
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentsegment profit2023-04-01 → 2023-06-30¥831m
—segment totalrevenue2023-04-01 → 2023-06-30¥57.9bn
—segment totalrevenue external2023-04-01 → 2023-06-30¥56.9bn
—segment totalrevenue intersegment2023-04-01 → 2023-06-30¥1.0bn
—segment totalsegment profit2023-04-01 → 2023-06-30¥18.0bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥1.7bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥1.7bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥471m
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue2022-04-01 → 2022-06-30¥5.5bn
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue external2022-04-01 → 2022-06-30¥5.2bn
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥267m
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentsegment profit2022-04-01 → 2022-06-30¥2.8bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue2022-04-01 → 2022-06-30¥7.2bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue external2022-04-01 → 2022-06-30¥7.0bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥162m
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentsegment profit2022-04-01 → 2022-06-30¥2.2bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue2022-04-01 → 2022-06-30¥20.2bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue external2022-04-01 → 2022-06-30¥19.3bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥951m
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentsegment profit2022-04-01 → 2022-06-30¥8.8bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue2022-04-01 → 2022-06-30¥14.9bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue external2022-04-01 → 2022-06-30¥14.9bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥2m
jpcrp040300-q1r_E05425-000Overseasreportable segmentsegment profit2022-04-01 → 2022-06-30¥4.0bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue2022-04-01 → 2022-06-30¥10.2bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue external2022-04-01 → 2022-06-30¥9.9bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥304m
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentsegment profit2022-04-01 → 2022-06-30¥1.4bn
—segment totalrevenue2022-04-01 → 2022-06-30¥58.0bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥56.3bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥1.7bn
—segment totalsegment profit2022-04-01 → 2022-06-30¥19.3bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 587
ItemContextValueUnit
Total transactions with owners IFRSCurrentYTDDuration_NonControllingInterestsIFRSMember3702000000JPY
Total transactions with owners IFRSCurrentYTDDuration-3787000000JPY
Equity IFRSCurrentQuarterInstant_ShareCapitalIFRSMember29196000000JPY
Equity IFRSCurrentQuarterInstant_CapitalSurplusIFRSMember30570000000JPY
Equity IFRSCurrentQuarterInstant_TreasurySharesIFRSMember-37000000JPY
Equity IFRSCurrentQuarterInstant_OtherComponentsOfEquityIFRSMember26361000000JPY
Equity IFRSCurrentQuarterInstant_RetainedEarningsIFRSMember230727000000JPY
Equity IFRSCurrentQuarterInstant_EquityAttributableToOwnersOfParentIFRSMember316817000000JPY
Equity IFRSCurrentQuarterInstant_NonControllingInterestsIFRSMember11964000000JPY
Equity IFRSCurrentQuarterInstant328780000000JPY
Profit loss before tax IFRSPrior1YTDDuration19748000000JPY
Profit loss before tax IFRSCurrentYTDDuration19831000000JPY
Depreciation and amortization ope cf IFRSPrior1YTDDuration1691000000JPY
Depreciation and amortization ope cf IFRSCurrentYTDDuration1986000000JPY
Finance income ope cf IFRSPrior1YTDDuration-1069000000JPY
Finance income ope cf IFRSCurrentYTDDuration-1892000000JPY
Finance costs ope cf IFRSPrior1YTDDuration16000000JPY
Finance costs ope cf IFRSCurrentYTDDuration65000000JPY
Share of loss profit of investments accounted for using equity method ope cf IFRSPrior1YTDDuration-190000000JPY
Share of loss profit of investments accounted for using equity method ope cf IFRSCurrentYTDDuration-45000000JPY
Change in financial assets measured at fair value through profit or loss ope cf IFRSPrior1YTDDuration31000000JPY
Change in financial assets measured at fair value through profit or loss ope cf IFRSCurrentYTDDuration-955000000JPY
Decrease increase in trade and other receivables ope cf IFRSPrior1YTDDuration3386000000JPY
Decrease increase in trade and other receivables ope cf IFRSCurrentYTDDuration2944000000JPY
Increase decrease in trade and other payables ope cf IFRSPrior1YTDDuration-715000000JPY
Increase decrease in trade and other payables ope cf IFRSCurrentYTDDuration233000000JPY
Increase decrease in provisons for customer loyalty program ope cf IFRSPrior1YTDDuration18000000JPY
Increase decrease in provisons for customer loyalty program ope cf IFRSCurrentYTDDuration67000000JPY
Decrease increase in other current assets ope cf IFRSPrior1YTDDuration-707000000JPY
Decrease increase in other current assets ope cf IFRSCurrentYTDDuration-56000000JPY
Other changes in working capital ope cf IFRSPrior1YTDDuration-2092000000JPY
Other changes in working capital ope cf IFRSCurrentYTDDuration-1247000000JPY
Subtotal ope cf IFRSPrior1YTDDuration20116000000JPY
Subtotal ope cf IFRSCurrentYTDDuration20932000000JPY
Dividends received ope cf IFRSPrior1YTDDuration34000000JPY
Dividends received ope cf IFRSCurrentYTDDuration65000000JPY
Interest received ope cf IFRSPrior1YTDDuration278000000JPY
Interest received ope cf IFRSCurrentYTDDuration416000000JPY
Interest paid ope cf IFRSPrior1YTDDuration-16000000JPY
Interest paid ope cf IFRSCurrentYTDDuration-65000000JPY
Income taxes refund paid ope cf IFRSPrior1YTDDuration-11017000000JPY
Income taxes refund paid ope cf IFRSCurrentYTDDuration-9387000000JPY
Net cash provided by used in operating activities IFRSPrior1YTDDuration9395000000JPY
Net cash provided by used in operating activities IFRSCurrentYTDDuration11962000000JPY
Payments into time deposits inv cf IFRSPrior1YTDDuration-6598000000JPY
Payments into time deposits inv cf IFRSCurrentYTDDuration-7760000000JPY
Proceeds from withdrawal of time deposits inv cf IFRSPrior1YTDDuration3842000000JPY
Proceeds from withdrawal of time deposits inv cf IFRSCurrentYTDDuration6485000000JPY
Purchase of financial assets measured at fair value inv cf IFRSPrior1YTDDuration-93000000JPY
Purchase of financial assets measured at fair value inv cf IFRSCurrentYTDDuration-1307000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-06-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass